Julia K. Mader, Austria

Medical University of Graz Division of Endocrinology and Diabetology
Julia Mader is Associate Professor of Medicine and Deputy Head of the Diabetes Outpatient Clinic at the Division of Endocrinology and Diabetology at the Medical University of Graz, Austria. She received her medical degree at the Medical University of Graz where she also trained in Internal Medicine, Endocrinology and Diabetology. Her research is focused on diabetes technology with emphasis on insulin pumps, continuous glucose monitoring, artificial pancreas and decision support systems for the treatment of diabetes.

Presenter of 4 Presentations

 Conference Calendar
INDUSTRY SESSION

Introduction

Date
Thu, 03.06.2021
Session Name
0390 - Plenary Industry Symposium 04 (Not Included In The Main Event CME/CPD Credit) (ID 42)
Lecture Time
12:20 - 12:25
Presenter
Authors
INDUSTRY SESSION

Personalising insulin therapy using smart pumps, pens and automated insulin delivery systems

Date
Thu, 03.06.2021
Session Name
0390 - Plenary Industry Symposium 04 (Not Included In The Main Event CME/CPD Credit) (ID 42)
Lecture Time
13:05 - 13:25
Presenter
Authors
INDUSTRY SESSION

Discussion & Closing

Date
Thu, 03.06.2021
Session Name
0390 - Plenary Industry Symposium 04 (Not Included In The Main Event CME/CPD Credit) (ID 42)
Lecture Time
13:40 - 13:50
Presenter
Authors
ORAL PRESENTATION SESSION

GLUCOSE TRACKING WITH OPTICAL MEASUREMENT IN CLINICAL EVALUATION—PROFUSA LUMEE GLUCOSE PLATFORM

Date
Sat, 05.06.2021
Session Name
0570 - Oral Presentation 15 (ID 74)
Lecture Time
15:45 - 15:55
Presenter
Authors

Abstract

Background and Aims

Profusa is developing a soft glucose-sensitive hydrogel, a sterile, small (5.0x0.75x0.65mm when hydrated), intended for subcutaneous injection. The hydrogel is suitable for long term use and could remain in the body permanently. Presented studies assess the platform function, transitioning from animal studies to human studies.

Methods

The glucose sensor is comprised of a hydrogel scaffold with covalently bound fluorescent molecules that produce near infrared light proportional to glucose concentration when interrogated by an optical reader placed on the skin (Figure 1). The v3.0 Reader utilizes a set of LEDs to excite fluorophores within the Hydrogel. The LEDs reside in the Reader which sits on the skin above the Hydrogel. The reader communicates wirelessly to a tablet for control and data transmission (Figure 2). Pre-clincal performance was validated in a swine mode in multiple 8-hour experiments over 3 months.Performance was assessed during in-clinic visits in subjects with diabetes over a period of 3 months. Frequent blood glucose measurements with a Super GL laboratory analyzer were collected as reference.

figure 1.pngfigure 2.png

Results

figure 3.pngfigure 4.pngfigure 5.pngThis study was designed to characterize baseline performance and signal perturbations due to environmental conditions, including motion, temperature, and ambient light. This characterization is used to develop and refine the signal processing algorithm to calculate glucose levels.The following graphs (Figures 3-5) demonstrate the successful identification of a glucose excursion in a single subject during the first two weeks.

Conclusions

Results of using this hydrogel and reader in the swine model are confirmed in this clinical study, tracking glucose during study days over a 3-month period.

Hide

Moderator of 1 Session

 Conference Calendar
INDUSTRY SESSION

Plenary Industry Symposium 04 (Not Included In The Main Event CME/CPD Credit)

Date
Thu, 03.06.2021
Session Type
INDUSTRY SESSION
Session Time
12:20 - 13:50
Room
Hall A
Chair(s)
Session Description

Advancing value-based personalised diabetes care in challenging time - Industry Symposium Supported by Roche